These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24573652)

  • 21. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
    Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
    Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
    Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
    Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
    Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
    Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization.
    Takai M; Kawakami K; Fujita Y; Kato T; Kato D; Iinuma K; Koie T; Ito M; Mizutani K
    Anticancer Res; 2021 Oct; 41(10):4753-4759. PubMed ID: 34593424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells.
    Chung BH; Lee HY; Lee JS; Young CY
    Cancer Lett; 2006 May; 236(2):222-8. PubMed ID: 16029925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
    Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
    Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
    Dart DA; Spencer-Dene B; Gamble SC; Waxman J; Bevan CL
    Endocr Relat Cancer; 2009 Dec; 16(4):1157-69. PubMed ID: 19635783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-androgen receptor signaling and prostate cancer inhibitory effects of sucrose- and benzophenone-compounds.
    Wang Z; Lee HJ; Wang L; Jiang C; Baek NI; Kim SH; Lü J
    Pharm Res; 2009 May; 26(5):1140-8. PubMed ID: 19266268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression.
    Kim SJ; Kim JM; Shim SH; Chang HI
    J Ethnopharmacol; 2014 Feb; 151(3):1064-1071. PubMed ID: 24384380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
    Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
    Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.